BioSpace News Archive

Ferring today announced that the FDA has approved ZOMACTON for Injection 5 mg and 10 mg recombinant human growth hormone indicated for replacement of GH in adults with GH deficiency.

Following the release, the company will hold an investment community conference call on the same day, beginning at 4:00 p.m. CT. Mark Gorder, president and chief executive officer, and Scott Longval, chief financial officer, will review the company’s financial performance and discuss its strategies.

Smithers Avanza, a boutique contract research organization (CRO) supporting the pharmaceutical and chemical industries, has named Robert L. Moore, Ph.D. to the position of Director, Business Development for Bioanalytical Services.

Total CF product revenues increased 29% to $2.17 billion from $1.68 billion for 2016.

CHOP Oncologists Update Analysis in Pivotal Global Trial of CAR T-Cell Treatment for Relapsed or Refractory ALL [31-January-2018] PHILADELPHIA, Jan. 31, 2018 /PRNewswire-USNewswire/ -- Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia

Centric Medical announced today that it will be participating in the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting which will be held March 6-10 in New Orleans, Louisiana, as well as the 76th Annual 2018 American College of Foot and Ankle Surgeons (ACFAS) Meeting to be held March 22-25 in Nashville, Tennessee.

Bursting oxygen-filled microbubbles in breast cancer makes tumors three times more sensitive to radiation therapy in preliminary tests with animal models of the disease [31-January-2018] PHILADELPHIA, Jan. 31, 2018 /PRNewswire/ -- Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to radiation therapy and improves

The competitive Phase I grant was awarded to Kinetic River in 2017 by the NIGMS.

Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.

Medidata and Syapse will jointly develop a portfolio of solutions to make it easier for cancer patients to access potentially life-saving clinical trials.